University of Kansas

Stowers Institute for Medical Research

University of Connecticut

The Childrens' Mercy Hospital

Anuradha Roy

Linheng Li

John M Perry

Xi C He

Emily E Scott

Scott J Weir

Xiuling Lu

Rajeswari Kasi

Gurusingham Sitta Sittampalam

Fang Tao

Tara Lin

The present disclosure provides, inter alia, methods for treating cancers including leukemia using low doses of an anthracycline such as doxorubicin.

Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells

The disclosure provides methods of treating cancer by selectively inhibiting p-S-&#x3b2;-catenin, p-T-&#x3b2;-catenin, p-T-&#x3b2;-catenin, and/or p-S-&#x3b2;-catenin production and/or activity. Such methods also and/or limit cancer-initiating cells.

Methods for treating chemoresistant cancer-initiating cells

A method of inhibiting formation of cancerous metabolites, of inhibiting cytochrome P450 2A13 from forming carcinogen metabolites, and/or inhibiting formation of cancerous lung cells in a subject can include: providing a morpholine compound that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6; administering a therapeutically effective amount of the morpholine compound or derivative to the subject. The morpholine compound or derivative can be substantially more selective for interacting with the cytochrome P450 2A13 over the cytochrome P450 2A6. The morpholine compound or derivative can also be substantially non-interactive with other physiological components. The morpholine compound or derivative can include a structure that selectively interacts with cytochrome P450 2A13 over cytochrome P450 2A6, such as Compounds 1-34 of Formulas A-D.

Morpholines as selective inhibitors of cytochrome P450 2A13

Growing community of inventors

Kansas City, MO, United States of America

Anuradha Roy